“The purposes of these updated Guidelines are to improve the perioperative management of blood transfusion and adjuvant therapies and to reduce the risk of adverse outcomes associated with transfusions, bleeding or anemia. The updated ASA practice guidelines differ from those published by other organizations in that: they include greater use of pharmacologic therapies to minimize blood transfusions, such as erythropoietin for the anemic patient, prothrombin complex concentrates for urgent reversal of warfarin, and intraoperative antifibrinolytic therapy during selected cardiac and noncardiac procedures having a high risk for bleeding. They advocate the use of transfusion algorithms, especially those based on thromboelastographic testing, blood-ordering schedules, and restrictive transfusion strategies. Why does this statement differ from existing guidelines? These ASA guidelines differ from the existing guidelines because they provide new evidence obtained from recent scientific literature along with findings from new surveys of expert consultants and randomly selected ASA members. Click here to read full-text.